Pediatric Myelodysplasia Medication

  • Author: Natalia Dixon, MD; Chief Editor: Robert J Arceci, MD, PhD   more...
 
Updated: Aug 3, 2011
 

Medication Summary

Several aspects of the management of pediatric myelodysplasia syndrome (MDS) differ from adult myelodysplasia therapy. Most importantly, the treatment goal must be curative because prolonging life by 5-8 years is not considered successful therapy in a healthy 10-year-old patient as it might in a 90-year-old patient who has other health problems. Therefore, allogeneic HSCT should almost always be the goal for children with myelodysplasia syndrome. However, the timing of HSCT is variable in children depending on symptomatology, disease characteristics, donor availability, and weighing the risks and benefits of transplant with the child’s quality of life.

The relevance of immunomodulating agents in pediatrics is investigational and remains unclear.

Various agents have been used to slow the progression of myelodysplasia syndrome, including low-dose cytosine arabinoside, cladribine (2-CdA), growth factors (erythropoietin, granulocyte colony-stimulating factor [G-CSF]), amifostine, and hydroxyurea. These agents are temporizing at best, and their role has been limited to palliation of myelodysplasia syndrome while a donor search takes place. In adults, decitabine, azacitidine, and lenalidomide (used primarily for 5q-syndrome) can reduce the need for transfusion and, in some cases, delay progression to AML when used in the correct subsets of patients.

Patients who present with a high percentage of marrow blasts and rapidly progressive disease may require chemotherapy while preparing for transplant. Both de novo and therapy-related myelodysplasia syndrome are usually only transiently responsive to conventional chemotherapy, which can be used in an attempt to keep the patient in remission until allogeneic HSCT can be performed. Transplantation from an HLA-matched family donor is optimal, but alternative donors should be considered when an HLA-matched family donor is not available.[33, 34]

Therapy prior to transplant also involves the judicious use of blood products and aggressive infection control because patients are often agranulocytic.

Next

DNA hypomethylating agents

Class Summary

These agents are indicated for myelodysplastic syndrome in adults.

View full drug information

Azacitidine (Vidaza)

 

Pyrimidine nucleoside analog of cytidine. Interferes with nucleic acid metabolism. Exerts antineoplastic effects by DNA hypomethylation and direct cytotoxicity on abnormal hematopoietic bone marrow cells. Hypomethylation may restore normal function to genes critical for cell differentiation and proliferation. Nonproliferative cells are largely insensitive to azacitidine. Indicated to treat MDS. FDA approved for all 5 MDS subtypes.

View full drug information

Decitabine (Dacogen)

 

Hypomethylating agent believed to exert antineoplastic effects by incorporating into DNA and inhibiting methyltransferase, resulting in hypomethylation. Hypomethylation in neoplastic cells may restore normal function to genes critical for cellular control of differentiation and proliferation. Indicated for treatment of MDS, including previously treated and untreated, de novo, and secondary MDS of all FAB subtypes (ie, RA, RARS, RAEB, RAEBT, CML) and IPSS groups intermediate-1 risk, intermediate-2 risk, and high risk.

Previous
Next

Immunomodulating agents

Class Summary

These agents are indicated for myelodysplasia syndrome in adults.

View full drug information

Lenalidomide (Revlimid)

 

Indicated for transfusion-dependent MDS subtype of deletion 5q31 cytogenetic abnormality. Structurally similar to thalidomide. Elicits immunomodulatory and antiangiogenic properties. Inhibits proinflammatory cytokine secretion and increases anti-inflammatory cytokines from peripheral blood mononuclear cells. The drug is FDA approved for adult patients with low or intermediate-1 IPSS category who are unlikely to respond to erythropoietin

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Natalia Dixon, MD  Assistant Professor, Department of Pediatrics, Division of Hematology and Oncology, Wake Forest University School of Medicine

Natalia Dixon, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Hematology, American Society of Pediatric Hematology/Oncology, and Children's Oncology Group

Disclosure: Nothing to disclose.

Coauthor(s)

Sharon M Castellino, MD, MSc, FAAP  Associate Professor, Department of Pediatrics, Section Pediatric Hematology-Oncology, Wake Forest University Health Sciences

Sharon M Castellino, MD, MSc, FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Society of Hematology, and American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Scott C Howard, MD  Associate Member, Department of Oncology, Director of Clinical Trials, International Outreach Program, St Jude Children's Research Hospital; Associate Professor, University of Tennessee Health Science Center College of Medicine

Scott C Howard, MD is a member of the following medical societies: American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Specialty Editor Board

Sharada A Sarnaik, MBBS  Professor of Pediatrics, Wayne State University School of Medicine; Director, Sickle Cell Center, Attending Hematologist/Oncologist, Children's Hospital of Michigan

Sharada A Sarnaik, MBBS is a member of the following medical societies: American Association of Blood Banks, American Association of University Professors, American Society of Hematology, American Society of Pediatric Hematology/Oncology, New York Academy of Sciences, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

James L Harper, MD  Associate Professor, Department of Pediatrics, Division of Hematology/Oncology and Bone Marrow Transplantation, Associate Chairman for Education, Department of Pediatrics, University of Nebraska Medical Center; Assistant Clinical Professor, Department of Pediatrics, Creighton University School of Medicine; Director, Continuing Medical Education, Children's Memorial Hospital; Pediatric Director, Nebraska Regional Hemophilia Treatment Center

James L Harper, MD is a member of the following medical societies: American Academy of Pediatrics, American Association for Cancer Research, American Federation for Clinical Research, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Council on Medical Student Education in Pediatrics, and Hemophilia and Thrombosis Research Society

Disclosure: Nothing to disclose.

Samuel Gross, MD  Professor Emeritus, Department of Pediatrics, University of Florida; Clinical Professor, Department of Pediatrics, University of North Carolina; Adjunct Professor, Department of Pediatrics, Duke University

Samuel Gross, MD is a member of the following medical societies: American Association for Cancer Research, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology, American Society of Hematology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Chief Editor

Robert J Arceci, MD, PhD  King Fahd Professor of Pediatric Oncology, Professor of Pediatrics, Oncology and the Cellular and Molecular Medicine Graduate Program, Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine

Robert J Arceci, MD, PhD is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Pediatric Society, American Society of Hematology, and American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Acknowledgments

The authors and editors of eMedicine gratefully acknowledge the contributions of previous authors Carmen Arkansas, MD, and Glenda Grawe, MD, to the development and writing of this article.

References

  1. Barlogie B, Johnston DA, Keating M, et al. Evolution of oligoleukemia. Cancer. May 15 1984;53(10):2115-24. [Medline].

  2. Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 3rd ed. International Agency for Research on Cancer (IARC); 2001.

  3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. Jun 1982;51(2):189-99. [Medline].

  4. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2008.

  5. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. Nov 5 2009;361(19):1872-85. [Medline].

  6. Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia--a review. Br J Haematol. Jan 2008;140(2):123-32. [Medline].

  7. Kalra R, Paderanga DC, Olson K, Shannon KM. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood. Nov 15 1994;84(10):3435-9. [Medline].

  8. Shannon KM, O'Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med. Mar 3 1994;330(9):597-601. [Medline].

  9. Ortmann CA, Niemeyer CM, Wawer A, Ebell W, Baumann I, Kratz CP. TERC mutations in children with refractory cytopenia. Haematologica. May 2006;91(5):707-8. [Medline].

  10. Marrone A, Sokhal P, Walne A, Beswick R, Kirwan M, Killick S, et al. Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations. Haematologica. Aug 2007;92(8):1013-20. [Medline].

  11. Vidal DO, Paixao VA, Brait M, et al. Aberrant methylation in pediatric myelodysplastic syndrome. Leuk Res. Feb 2007;31(2):175-81. [Medline].

  12. Hasle H, Kerndrup G, Jacobsen BB. Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia. Sep 1995;9(9):1569-72. [Medline].

  13. Emanuel PD. Myelodysplasia and myeloproliferative disorders in childhood: an update. Br J Haematol. Jun 1999;105(4):852-63. [Medline].

  14. Hasle H, Jacobsen BB, Pedersen NT. Myelodysplastic syndromes in childhood: a population based study of nine cases. Br J Haematol. Aug 1992;81(4):495-8. [Medline].

  15. Passmore SJ, Chessells JM, Kempski H, Hann IM, Brownbill PA, Stiller CA. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol. Jun 2003;121(5):758-67. [Medline].

  16. Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004;118-45. [Medline].

  17. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. Oct 1992;82(2):358-67. [Medline].

  18. Arico M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood. Jul 15 1997;90(2):479-88. [Medline].

  19. Kardos G, Baumann I, Passmore SJ, Locatelli F, Hasle H, Schultz KR. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood. Sep 15 2003;102(6):1997-2003. [Medline].

  20. Bhatia S, Krailo MD, Chen Z, Burden L, Askin FB, Dickman PS, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood. 2007;109(1):46-51.

  21. Hasle H. Myelodysplastic and myeloproliferative disorders in children. Curr Opin Pediatr. Feb 2007;19(1):1-8. [Medline].

  22. Barnard DR, Woods WG. Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer--an update. Leuk Lymphoma. May 2005;46(5):651-63. [Medline].

  23. Teo JT, Klaassen R, Fernandez CV, Yanofsky R, Wu J, Champagne J. Clinical and genetic analysis of unclassifiable inherited bone marrow failure syndromes. Pediatrics. Jul 2008;122(1):e139-48. [Medline].

  24. Auletta JJ, Shurin S. Improved hematopoiesis using amifostine in secondary myelodysplasia. J Pediatr Hematol Oncol. Nov-Dec 1999;21(6):531-4. [Medline].

  25. Bader-Meunier B, Mielot F, Tchernia G, et al. Myelodysplastic syndromes in childhood: report of 49 patients from a French multicentre study. French Society of Paediatric Haematology and Immunology. Br J Haematol. Feb 1996;92(2):344-50. [Medline].

  26. Mandel K, Dror Y, Poon A, Freedman MH. A practical, comprehensive classification for pediatric myelodysplastic syndromes: the CCC system. J Pediatr Hematol Oncol. Oct 2002;24(7):596-605. [Medline].

  27. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. Feb 2003;17(2):277-82. [Medline].

  28. Occhipinti E, Correa H, Yu L, Craver R. Comparison of two new classifications for pediatric myelodysplastic and myeloproliferative disorders. Pediatr Blood Cancer. Mar 2005;44(3):240-4. [Medline].

  29. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. Jul 30 2009;114(5):937-51. [Medline].

  30. Vardiman JW. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2006;199-204. [Medline].

  31. Gupta V, Brooker C, Tooze JA, Yi QL, Sage D, Turner D. Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults. Br J Haematol. Jul 2006;134(1):95-9. [Medline].

  32. Bierings M, Nachman JB, Zwaan CM. Stem cell transplantation in pediatric leukemia and myelodysplasia: state of the art and current challenges. Curr Stem Cell Res Ther. Jan 2007;2(1):53-63. [Medline].

  33. Bunin N, Saunders F, Leahey A, et al. Alternative donor bone marrow transplantation for children with juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol. Nov-Dec 1999;21(6):479-85. [Medline].

  34. Kalwak K, Wojcik D, Gorczynska E, et al. Allogeneic hematopoietic cell transplantation from alternative donors in children with myelodysplastic syndrome: is that an alternative?. Transplant Proc. Jun 2004;36(5):1574-7. [Medline].

  35. Mantadakis E, Shannon KM, Singer DA, Finklestein J, Chan KW, Hilden JM. Transient monosomy 7: a case series in children and review of the literature. Cancer. Jun 15 1999;85(12):2655-61. [Medline].

  36. Barnard DR, Alonzo TA, Gerbing RB, Lange B, Woods WG. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group. Pediatr Blood Cancer. Jul 2007;49(1):17-22. [Medline].

  37. Bennett JM. Classification of the myelodysplastic syndromes. Clin Haematol. Nov 1986;15(4):909-23. [Medline].

  38. Boogaerts MA, Nelissen V, Roelant C, Goossens W. Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol. Oct 1983;55(2):217-27. [Medline].

  39. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. Jul 15 2006;108(2):419-25. [Medline].

  40. Clark R, Peters S, Hoy T, et al. Prognostic importance of hypodiploid hemopoietic precursors in myelodysplastic syndromes. N Engl J Med. Jun 5 1986;314(23):1472-5. [Medline].

  41. De Witte T, Van Biezen A, Hermans J, et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood. Nov 15 1997;90(10):3853-7. [Medline]. [Full Text].

  42. Dewald GW, Pierre RV, Phyliky RL. Three patients with structurally abnormal X chromosomes, each with Xq13 breakpoints and a history of idiopathic acquired sideroblastic anemia. Blood. Jan 1982;59(1):100-5. [Medline].

  43. Fohlmeister I, Fischer R, Mödder B, Rister M, Schaefer HE. Aplastic anaemia and the hypocellular myelodysplastic syndrome: histomorphological, diagnostic, and prognostic features. J Clin Pathol. Nov 1985;38(11):1218-24. [Medline]. [Full Text].

  44. Freedman MH, Bonilla MA, Fier C, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood. Jul 15 2000;96(2):429-36. [Medline]. [Full Text].

  45. Golde DW. The stem cell. Sci Am. Dec 1991;265(6):86-93. [Medline].

  46. Hasegawa D, Manabe A, Kubota T, et al. Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia. Br J Haematol. Mar 2005;128(6):805-12. [Medline].

  47. Hasle H, Arico M, Basso G, et al. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS). Leukemia. Mar 1999;13(3):376-85. [Medline].

  48. Hasle H, Baumann I, Bergstrasser E, et al. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia. Dec 2004;18(12):2008-14. [Medline].

  49. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. May 27 1999;340(21):1649-60. [Medline].

  50. Hofmann WK, Ottmann OG, Ganser A, Hoelzer D. Myelodysplastic syndromes: clinical features. Semin Hematol. Jul 1996;33(3):177-85. [Medline].

  51. Ingram W, Lim ZY, Mufti GJ. Allogeneic transplantation for myelodysplastic syndrome (MDS). Blood Rev. Jun 5 2006;[Medline].

  52. Jackson GH, Carey PJ, Cant AJ, et al. Myelodysplastic syndromes in children [letter]. Br J Haematol. May 1993;84(1):185-6. [Medline].

  53. Jacobs RH, Cornbleet MA, Vardiman JW, et al. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood. Jun 1986;67(6):1765-72. [Medline].

  54. Juneja SK, Imbert M, Jouault H, Scoazec JY, Sigaux F, Sultan C. Haematological features of primary myelodysplastic syndromes (PMDS) at initial presentation: a study of 118 cases. J Clin Pathol. Oct 1983;36(10):1129-35. [Medline]. [Full Text].

  55. Kahn A. Abnormalities of erythrocyte enzymes in dyserythropoiesis and malignancies. Clin Haematol. Feb 1981;10(1):123-38. [Medline].

  56. Koeffler HP, Golde DW. Human preleukemia. Ann Intern Med. Aug 1980;93(2):347-53. [Medline].

  57. Larson RA. Myelodysplasia: when to treat and how. Best Pract Res Clin Haematol. 2006;19(2):293-300. [Medline].

  58. Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood. Aug 27 2009;114(9):1859-63. [Medline].

  59. Luna-Fineman S, Shannon KM, Atwater SK, et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood. Jan 15 1999;93(2):459-66. [Medline]. [Full Text].

  60. Luna-Fineman S, Shannon KM, Lange BJ. Childhood monosomy 7: epidemiology, biology, and mechanistic implications. Blood. Apr 15 1995;85(8):1985-99. [Medline]. [Full Text].

  61. Maldonado JE, Maigne J, Lecoq D. Comparative electron-microscopic study of the erythrocytic line in refractory anemia (preleukemia) and myelomonocytic leukemia. Nouv Rev Fr Hematol Blood Cells. 1976;17(1-2):167-85. [Medline].

  62. Martin S, Baldock SC, Ghoneim AT, Child JA. Defective neutrophil function and microbicidal mechanisms in the myelodysplastic disorders. J Clin Pathol. Oct 1983;36(10):1120-8. [Medline]. [Full Text].

  63. McKenna RW. Myelodysplasia and myeloproliferative disorders in children. Am J Clin Pathol. Dec 2004;122 Suppl:S58-69. [Medline].

  64. Mecucci C, Tricot G, Boogaerts M, Van den Berghe H. An identical translocation between chromosome 1 and 15 in two patients with myelodysplastic syndromes [published erratum appears in Br J Haematol 1987 Apr;65(4):508]. Br J Haematol. Mar 1986;62(3):439-45. [Medline].

  65. Moir DJ, Jones PA, Pearson J, et al. A new translocation, t(1;3) (p36;q21), in myelodysplastic disorders. Blood. Aug 1984;64(2):553-5. [Medline].

  66. Nand S, Godwin JE. Hypoplastic myelodysplastic syndrome. Cancer. Sep 1 1988;62(5):958-64. [Medline].

  67. Negendank W, Weissman D, Bey TM, et al. Evidence for clonal disease by magnetic resonance imaging in patients with hypoplastic marrow disorders. Blood. Dec 1 1991;78(11):2872-9. [Medline]. [Full Text].

  68. Newman DR, Pierre RV, Linman JW. Studies on the diagnostic significance of hemoglobin F levels. Mayo Clin Proc. Mar 1973;48(3):199-202. [Medline].

  69. Niemeyer CM, Baumann I. Myelodysplastic syndrome in children and adolescents. Semin Hematol. Jan 2008;45(1):60-70. [Medline].

  70. O'Donnell MR, Nademanee AP, Snyder DS, et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol. Nov 1987;5(11):1822-6. [Medline].

  71. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood. Jun 1 1993;81(11):2844-53. [Medline].

  72. Passmore SJ, Hann IM, Stiller CA, et al. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood. Apr 1 1995;85(7):1742-50. [Medline]. [Full Text].

  73. Raskind WH, Tirumali N, Jacobson R, et al. Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood. Jun 1984;63(6):1318-23. [Medline].

  74. Rosenthal DS, Moloney WC. Refractory dysmyelopoietic anemia and acute leukemia. Blood. Feb 1984;63(2):314-8. [Medline].

  75. Russell NH, Keenan JP, Bellingham AJ. Thrombocytopathy in preleukaemia: association with a defect of thromboxane A2 activity. Br J Haematol. Mar 1979;41(3):417-25. [Medline].

  76. Ruter B, Wijermans PW, Lubbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer. Apr 15 2006;106(8):1744-50. [Medline].

  77. Sasaki H, Manabe A, Kojima S, et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia. Nov 2001;15(11):1713-20. [Medline].

  78. Scheres JM, Hustinx TW, Holdrinet RS, et al. Translocation 1;7 in dyshematopoiesis: possibly induced with a nonrandom geographic distribution. Cancer Genet Cytogenet. Aug 1984;12(4):283-94. [Medline].

  79. Schulman I, Pierce M. Studies on thrombopoiesis.I.A factor in normal plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood. 1960;16:943.

  80. Scoazec JY, Imbert M, Crofts M, et al. Myelodysplastic syndrome or acute myeloid leukemia? A study of 28 cases presenting with borderline features. Cancer. May 15 1985;55(10):2390-4. [Medline].

  81. Silverman LR, Mufti GJ. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat Clin Pract Oncol. Dec 2005;2 Suppl 1:S12-23. [Medline].

  82. Sun EC, Yen YM, Ip T, Otsuka NY. Peripheral circulation in patients with myelodysplasia. J Pediatr Orthop. Nov-Dec 2003;23(6):714-7. [Medline].

  83. Takagi S, Tanaka O, Origasa H, Miura Y. Prognostic significance of magnetic resonance imaging of femoral marrow in patients with myelodysplastic syndromes. J Clin Oncol. Jan 1999;17(1):277-83. [Medline].

  84. Tricot G, De Wolf-Peeters C, Hendrickx B, Verwilghen RL. Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears. Br J Haematol. Jul 1984;57(3):423-30. [Medline].

  85. Tricot G, De Wolf-Peeters C, Vlietinck R, Verwilghen RL. Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol. Oct 1984;58(2):217-25. [Medline].

  86. Tricot G, De Wolf-Peeters C, Vlietinck R, Verwilghen RL. The importance of bone marrow biopsy in myelodysplastic disorders. Bibl Haematol. 1984;(50):31-40. [Medline].

  87. Woodard P, Barfield R, Hale G, et al. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Pediatr Blood Cancer. Sep 9 2005;[Medline].

  88. Woods WG, Barnard DR, Alonzo TA, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol. Jan 15 2002;20(2):434-40. [Medline].

  89. Woolfrey AE, Gooley TA, Sievers EL, et al. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome. Blood. Nov 15 1998;92(10):3546-56. [Medline]. [Full Text].

  90. Yoshida Y, Oguma S, Uchino H, Maekawa T. Refractory myelodysplastic anaemias with hypocellular bone marrow. J Clin Pathol. Jul 1988;41(7):763-7. [Medline]. [Full Text].

  91. Yusuf U, Frangoul HA, Gooley TA, et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant. Apr 2004;33(8):805-14. [Medline].

 
Previous
Next
 
Morphological findings of refractory cytopenia of childhood.
Morphological findings of hypoplastic refractory cytopenia of childhood and aplastic anemia of childhood.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.